Key facts
- This page summarizes Douglas E. Williams's Form 4 filing for Codiak BioSciences, Inc..
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 21 Feb 2023, 15:32.
Douglas E. Williams - 16 Aug 2022 Form 4 Insider Report for Codiak BioSciences, Inc.
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 16 Aug 2022
- Net transaction value
- -$20,288
- SEC form
- 4
- Accepted by SEC
- 21 Feb 2023, 15:32:03 UTC
- Prior SEC filing
- 18 Feb 2022
- Next SEC filing
- 23 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yalonda Howze, Attorney-in-Fact for Douglas E. Williams
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Douglas E. Williams filed Form 4 for Codiak BioSciences, Inc. on 21 Feb 2023.
Change
- Previous filing in this sequence was filed on 18 Feb 2022.
- Current net transaction value: -$20,288.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CDAKQ
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +22,969
- Change %
- +126%
- Price
- Shares after
- 41,146
- Date
- 16 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
CDAKQ
transaction
Common Stock
Sale
- Transaction value
- $15,739
- Shares
- -7,112
- Change %
- -17%
- Price
- $2.21*
- Shares after
- 34,034
- Date
- 17 Aug 2022
- Ownership
- Direct
- Footnotes
- F2
CDAKQ
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +22,969
- Change %
- +67%
- Price
- Shares after
- 57,003
- Date
- 16 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
CDAKQ
transaction
Common Stock
Sale
- Transaction value
- $4,549
- Shares
- -7,681
- Change %
- -13%
- Price
- $0.5922*
- Shares after
- 49,322
- Date
- 17 Feb 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CDAKQ
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -22,969
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 68,906
- Date
- 16 Aug 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,969
- Exercise price
- Footnotes
- F3, F4
CDAKQ
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -22,969
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 45,937
- Date
- 16 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,969
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Footnote F2
The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
Footnote F3
Each RSU represents a contingent right to receive one share of common stock.
Footnote F4
On February 16, 2022, the reporting person was granted 91,875 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.